zuvius life sciences

Graniz (Granisetron Hydrochloride Injection 3 mg) is a prescription medicine containing Granisetron Hydrochloride, a 5-HT3 (serotonin) receptor antagonist used to help prevent and treat nausea and vomiting associated with chemotherapy, radiotherapy, and surgery. It works by blocking serotonin receptors that trigger nausea and vomiting, providing effective symptom control during cancer treatment and the perioperative period. Graniz is administered by qualified healthcare professionals through intravenous (IV) injection or infusion. The dosage and timing are determined by the treating physician based on the patient's age, medical condition, and treatment regimen. Key Benefits Contains Granisetron Hydrochloride 3 mg, a proven antiemetic. Helps prevent chemotherapy-induced nausea and vomiting (CINV). Effective in reducing radiotherapy-induced nausea and vomiting (RINV). May be used to prevent and treat postoperative nausea and vomiting (PONV). Sterile injectable formulation for hospital and clinical use. Manufactured according to high pharmaceutical quality standards. Indications Graniz (Granisetron Hydrochloride Injection 3 mg) may be prescribed for: Prevention of chemotherapy-induced nausea and vomiting (CINV). Prevention and treatment of radiotherapy-induced nausea and vomiting (RINV). Prevention and treatment of postoperative nausea and vomiting (PONV). Administration For intravenous (IV) administration by trained healthcare professionals. Dosage is individualized based on the patient's clinical condition and treatment protocol. Follow the prescribing physician's instructions regarding administration and monitoring.

Dactinoz (Dacarbazine Injection) is a prescription chemotherapy medicine containing Dacarbazine, an alkylating agent used to treat certain types of cancer. It works by damaging the DNA of rapidly dividing cancer cells, helping to slow or stop their growth. Dacarbazine is commonly used as part of combination chemotherapy regimens under the supervision of experienced oncology specialists. It is administered in hospitals or specialized cancer treatment centers. (medlineplus.gov) Dactinoz is given by intravenous (IV) infusion by qualified healthcare professionals. The dosage and treatment schedule are determined by the oncologist based on the patient's cancer type, body surface area, overall health, and treatment protocol. Key Benefits Contains Dacarbazine, a well-established anticancer medicine. Used in combination chemotherapy regimens for selected cancers. Administered under specialist oncology supervision. Sterile injectable formulation for hospital use. Indications Dactinoz (Dacarbazine Injection) may be prescribed for the treatment of: Metastatic malignant melanoma (advanced skin cancer) Hodgkin lymphoma, typically as part of combination regimens such as ABVD (Adriamycin, Bleomycin, Vinblastine, and Dacarbazine). (medlineplus.gov) Administration For intravenous (IV) use only. Must be administered by trained healthcare professionals in an oncology setting. Regular monitoring of blood counts, liver function, kidney function, and overall clinical condition is required during treatment due to the potential for serious side effects. Storage Store according to the manufacturer's recommendations. Protect from light where specified, and keep out of reach of children. Reconstitution and handling should be performed using appropriate cytotoxic safety precautions. Important: Dactinoz (Dacarbazine Injection) is a prescription-only chemotherapy medicine. It should only be used under the guidance of a qualified oncologist with appropriate monitoring for safety and treatment response.

Azath (Azathioprine Tablet) contains Azathioprine, an immunosuppressive medicine used to reduce the activity of the body's immune system. It is commonly prescribed to prevent organ transplant rejection and to manage various autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), lupus, autoimmune hepatitis, and certain skin disorders. Azathioprine helps control inflammation and prevents the immune system from attacking healthy tissues. Azath tablets should only be taken under the supervision of a qualified healthcare professional. Regular blood tests are essential during treatment to monitor blood cell counts and liver function, as the medicine may increase the risk of infections and other side effects. Key Benefits Helps prevent organ transplant rejection. Reduces inflammation in autoimmune diseases. Controls symptoms of rheumatoid arthritis. Supports long-term management of Crohn's disease and ulcerative colitis. Decreases the need for long-term corticosteroid therapy in some patients. Uses of Azath (Azathioprine Tablet) Organ transplant rejection prevention Rheumatoid arthritis Crohn's disease Ulcerative colitis Systemic lupus erythematosus (SLE) Autoimmune hepatitis Autoimmune skin disorders How It Works Azathioprine is converted in the body into active metabolites that suppress the production and activity of immune cells. This reduces the immune response, helping prevent tissue damage caused by autoimmune diseases and reducing the risk of organ rejection after transplantation. Dosage & Administration Take exactly as prescribed by your healthcare provider. Swallow the tablet whole with water, preferably after food to reduce stomach upset. Take it at the same time each day. Do not stop treatment without medical advice. Possible Side Effects Common side effects may include: Nausea or vomiting Loss of appetite Mild stomach discomfort Increased susceptibility to infections Fatigue Temporary hair thinning Seek immediate medical attention if you experience persistent fever, unusual bleeding or bruising, severe abdominal pain, yellowing of the skin or eyes, or signs of a serious infection. Precautions Regular blood tests are required during treatment. Inform your doctor if you have liver disease, kidney disease, or an active infection. Avoid live vaccines unless advised by your healthcare provider. Use effective contraception during treatment if recommended. Inform your healthcare provider about all medications you are taking, as Azathioprine has significant drug interactions.

Aprepet-Z Combi Pack Capsules contain Aprepitant, a Neurokinin-1 (NK1) receptor antagonist used to prevent nausea and vomiting caused by cancer chemotherapy (CINV). It is prescribed as part of a combination antiemetic regimen along with a 5-HT3 receptor antagonist (such as ondansetron) and dexamethasone to provide effective protection against both acute and delayed chemotherapy-induced nausea and vomiting. The standard combi pack contains one 125 mg capsule (Day 1) and two 80 mg capsules (Days 2 and 3). Key Benefits Helps prevent chemotherapy-induced nausea and vomiting (CINV) Controls both acute and delayed nausea after chemotherapy Improves patient comfort and adherence to cancer treatment Used with other antiemetic medicines for enhanced effectiveness Convenient 3-day dosing schedule Composition Day 1: Aprepitant 125 mg Capsule Day 2: Aprepitant 80 mg Capsule Day 3: Aprepitant 80 mg Capsule Indications Prevention of nausea and vomiting associated with highly emetogenic chemotherapy (HEC) Prevention of nausea and vomiting associated with moderately emetogenic chemotherapy (MEC) In some cases, aprepitant is also used to help prevent postoperative nausea and vomiting in adults. How It Works Aprepitant blocks Neurokinin-1 (NK1) receptors in the brain, preventing the action of substance P, a chemical involved in triggering nausea and vomiting. When combined with other antiemetic medicines, it provides comprehensive protection throughout the chemotherapy cycle. Dosage Take the capsules exactly as prescribed by your oncologist: Day 1: One 125 mg capsule approximately 1 hour before chemotherapy Days 2 & 3: One 80 mg capsule each morning The capsules may be taken with or without food and should be swallowed whole. Possible Side Effects Common side effects may include: Headache Constipation Fatigue Hiccups Loss of appetite Indigestion Mild elevation of liver enzymes Seek medical attention if you experience signs of an allergic reaction or severe side effects. Precautions Use only under the supervision of an oncologist. Inform your doctor about all medicines you are taking, as aprepitant has significant drug interactions (especially with CYP3A4-metabolized medicines). Women using hormonal contraceptives should use an additional non-hormonal contraceptive method during treatment and for one month after the last dose. Tell your healthcare provider if you have liver disease, are pregnant, or are breastfeeding

Antifol (Pemetrexed Injection) is a prescription chemotherapy medicine containing Pemetrexed, an antifolate antineoplastic agent used to treat specific types of cancer. It works by blocking enzymes that cancer cells need to produce DNA and RNA, slowing or stopping the growth of rapidly dividing cancer cells. Pemetrexed is commonly used alone or in combination with other anticancer medicines depending on the type and stage of cancer. Uses of Antifol (Pemetrexed Injection) Non-squamous Non-Small Cell Lung Cancer (NSCLC) Malignant Pleural Mesothelioma Maintenance treatment for advanced NSCLC after initial chemotherapy Advanced or metastatic lung cancer in combination with platinum-based chemotherapy and other approved therapies, as recommended by an oncologist. How It Works Pemetrexed inhibits multiple folate-dependent enzymes involved in DNA and RNA synthesis. This prevents cancer cells from growing and multiplying, leading to their destruction while helping to slow disease progression. Administration Given as an intravenous (IV) infusion by a qualified healthcare professional. Treatment is usually administered in 21-day cycles, depending on the patient's condition and treatment plan. Patients are typically prescribed folic acid, vitamin B12, and dexamethasone to reduce the risk of treatment-related side effects. Possible Side Effects Common side effects may include: Fatigue Nausea and vomiting Loss of appetite Mouth sores Low white blood cell count (neutropenia) Anemia Low platelet count Skin rash Increased risk of infection Seek immediate medical attention if severe fever, unusual bleeding, difficulty breathing, or allergic reactions occur. Precautions Use only under the supervision of an experienced oncologist. Regular blood tests and kidney function monitoring are required during treatment. Inform your healthcare provider about all medications and existing medical conditions before starting therapy. Avoid pregnancy during treatment and follow your doctor's advice regarding contraception. Patients with significant kidney impairment may not be suitable candidates for treatment.

Anastroz Tab 1 mg contains Anastrozole 1 mg, a prescription aromatase inhibitor primarily used for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It works by reducing the production of estrogen in the body, helping slow or stop the growth of estrogen-dependent breast cancer cells. Anastrozole is commonly prescribed as adjuvant therapy after surgery or as a first-line treatment for advanced or metastatic breast cancer. Key Benefits Helps reduce estrogen levels in postmenopausal women. Used to treat early-stage and advanced hormone receptor-positive breast cancer. May reduce the risk of breast cancer recurrence after surgery. Can be used as first-line therapy for metastatic breast cancer. Convenient once-daily oral tablet dosage. How It Works Anastrozole belongs to the aromatase inhibitor class of medicines. It blocks the aromatase enzyme responsible for converting androgens into estrogen. Lower estrogen levels help prevent the growth and spread of hormone-sensitive breast cancer cells. Dosage & Administration Usual adult dose: 1 mg tablet once daily, or as directed by an oncologist. May be taken with or without food. Swallow the tablet whole with water. Continue treatment for the duration prescribed by your healthcare provider. Possible Side Effects Common side effects may include: Hot flashes Joint or muscle pain Weakness or fatigue Nausea Headache Skin rash Reduced bone mineral density (osteoporosis) with long-term use Precautions For use only in postmenopausal women unless specifically prescribed. Not recommended during pregnancy or breastfeeding. Inform your doctor if you have osteoporosis, liver disease, or kidney disease. Regular monitoring of bone health may be recommended during long-term treatment. Use only under medical supervision.

Acalataz Capsules 100 mg contain Acalabrutinib 100 mg, a targeted anticancer medicine used for the treatment of specific B-cell blood cancers. It belongs to a class of medicines known as Bruton's Tyrosine Kinase (BTK) inhibitors, which work by blocking the BTK protein responsible for the growth and survival of abnormal B-cells. This action helps slow or stop the progression of certain blood cancers. Key Benefits Targeted therapy for B-cell malignancies Helps slow cancer cell growth and spread May improve progression-free survival in eligible patients Oral capsule for convenient at-home treatment under specialist supervision Indications Acalataz (Acalabrutinib) 100 mg is prescribed for adults with: Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL) Mantle Cell Lymphoma (MCL), in appropriate treatment settings as determined by the treating oncologist. How It Works Acalabrutinib selectively inhibits Bruton's Tyrosine Kinase (BTK), an enzyme involved in B-cell receptor signaling. Blocking BTK prevents cancerous B-cells from receiving growth and survival signals, reducing their multiplication and promoting cancer control. Dosage Strength: 100 mg Dosage should be taken exactly as prescribed by an oncologist. Swallow the capsule whole with water. It may be taken with or without food. Do not crush, chew, or open the capsule. Possible Side Effects Some patients may experience: Headache Fatigue Diarrhea Muscle or joint pain Bruising or bleeding Upper respiratory tract infections Low blood cell counts Seek immediate medical attention if severe bleeding, persistent fever, irregular heartbeat, or signs of infection occur. Precautions Use only under the supervision of a qualified oncologist. Inform your doctor about all medicines you are taking, especially blood thinners and CYP3A-interacting drugs. Regular blood tests may be required during treatment. Avoid use during pregnancy unless specifically advised by your healthcare provider. Breastfeeding is generally not recommended during treatment